<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/60C80373-4229-4346-9049-52D9717361F8"><gtr:id>60C80373-4229-4346-9049-52D9717361F8</gtr:id><gtr:name>UCL Institute of Child Health and Institute of Cancer Research, Sutton</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/90E10C07-7B4F-45DD-AA82-4D008528D8DD"><gtr:id>90E10C07-7B4F-45DD-AA82-4D008528D8DD</gtr:id><gtr:name>Constellation Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5B9602DA-AB9C-4AB7-89DA-949F5BDEB1FE"><gtr:id>5B9602DA-AB9C-4AB7-89DA-949F5BDEB1FE</gtr:id><gtr:name>Roche Pharmaceuticals</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/60C80373-4229-4346-9049-52D9717361F8"><gtr:id>60C80373-4229-4346-9049-52D9717361F8</gtr:id><gtr:name>UCL Institute of Child Health and Institute of Cancer Research, Sutton</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/90E10C07-7B4F-45DD-AA82-4D008528D8DD"><gtr:id>90E10C07-7B4F-45DD-AA82-4D008528D8DD</gtr:id><gtr:name>Constellation Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5B9602DA-AB9C-4AB7-89DA-949F5BDEB1FE"><gtr:id>5B9602DA-AB9C-4AB7-89DA-949F5BDEB1FE</gtr:id><gtr:name>Roche Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/20FADCBA-6421-4677-BB85-FF509B0AD9E3"><gtr:id>20FADCBA-6421-4677-BB85-FF509B0AD9E3</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Adams</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1100054"><gtr:id>55FCD7B0-16FD-4250-A486-3260AFB54C84</gtr:id><gtr:title>Tumor suppression by chromatin regulators.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100054</gtr:grantReference><gtr:abstractText>Cell senescence is an irreversible cell growth arrest that stops proliferation of damaged pre-cancerous cells. For example, benign human moles ? or nevi - contain damaged pre-cancerous pigmented melanocytes. Nevi rarely progress to cancer because the melanocytes are held in a growth arrested senescent state. 

Chromatin is a complex matrix of DNA and proteins packaged tightly into the cell nucleus. Genetic information is encoded within the DNA. Additional epigenetic information is encoded within the proteins and higher order folding patterns that also contribute to chromatin. Both genetic and epigenetic information are important for proper cell, tissue and organismal function, and dysregulation of either can contribute to disease states, such as cancer. Epigenetic information is an attractive target for cancer research, because epigenetic alterations are thought to be more reversible than genetic ones, and so are a rationale basis for design of anti-cancer therapies. 

This application investigates the role of two chromatin regulatory complexes, the HUCA complex and the Brg1/Snf5 complex, that are implicated in suppression of cancer by virtue of their ability activate cell senescence. Recent whole genome analyses from our lab have uncovered a likely functional link between the HUCA and Brg1/Snf5 complexes. The goal of this application is to dissect the mechanisms by which HUCA and Brg1/Snf5 collaborate to regulate chromatin structure and induce cell senescence and tumor suppression. 

Of particular note, inactivation of the Snf5 protein is a primary cause of malignant rhabdoid tumors in children. This research should enhance our understanding of this and other cancers, and so promote development of improved diagnostic, prognostic and therapeutic strategies.</gtr:abstractText><gtr:technicalSummary>Oncogene-induced cellular senescence (OIS) is a permanent cell growth arrest caused by an activated oncogene in a primary untransformed cell. OIS is a potent tumor suppression mechanism. Senescence depends on profound changes in chromatin structure. Two chromatin regulatory complexes implicated in control of senescence are the HIRA/UBN1/CABIN1/ASF1a (HUCA) histone chaperone complex and the Brg1/Snf5 chromatin-remodeling complex. HUCA is a histone chaperone that deposits the histone variant, histone H3.3, at transcription start sites and other gene regulatory sites. Since histone H3.3-containing nucleosomes are unstable, this promotes transcription activation. The Brg1/Snf5 complex reshapes chromatin in an ATP-dependent manner, and this also frequently results in transcription activation. Consistent with a role in senescence, the Brg1/Snf5 complex has potent tumor suppressor activity in humans and mouse models. However, the relationship between HUCA and Brg1/Snf5 as regulators of gene transcription and senescence is unknown. 

Recently, through unbiased, whole-genome ChIP coupled to massively parallel sequencing (ChIP-seq) we discovered a striking overlap between HUCA and Brg1/Snf5 across the human genome. Accordingly, we hypothesize that Brg1/Snf5 and HUCA are intimately associated as regulators of chromatin structure and function. In particular, we hypothesize that HUCA and Brg1/Snf5 collaborate to regulate the onset of cell senescence. We will test this hypothesis as follows:

Aim 1. Compare physical and functional overlap of HUCA and Brg1/Snf5 complexes in proliferating and senescent cells. 

Aim 2. Investigate physical and mechanistic interactions between HUCA and Brg1/Snf5 in vitro. 

Aim 3. Investigate functional and mechanistic interactions between HUCA and Brg1/Snf5 in vivo.</gtr:technicalSummary><gtr:fund><gtr:end>2015-01-03</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>524199</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Roche Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Investigation of BET and MDM2 inhibitors as a candidate novel combination therapy for Acute Myeloid Leukaemia</gtr:description><gtr:id>6114B9F3-91E9-4722-AE88-71CEE9EC7AB9</gtr:id><gtr:impact>Application for funding submitted to MRC. Goal is to progress studies to a Phase I clinical trial of the drug combination in AML.</gtr:impact><gtr:partnerContribution>Roche and Constellation provided intellectual advice on use of drugs and free human clinical grade drugs (RG7112 and CPI0610) for use in mouse models. 

Roche also provided 1 year funding for a technician in my lab, Ms. Maria Terradas Terradas</gtr:partnerContribution><gtr:piContribution>My lab performed all the studies in vitro and in mouse models to demonstrate the synergy between MDM2 inhibitors and BET inhibitors against AML.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCL Institute of Child Health and Institute of Cancer Research, Sutton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Testing MEK inhibitors in Congenitcal Melanocytic Nevus Syndrome</gtr:description><gtr:id>8668B0BA-0D3E-4051-BD5D-10984941133D</gtr:id><gtr:impact>Pawlikowski et al, 2015, PNAS.</gtr:impact><gtr:partnerContribution>Dr. Kinsler sequenced germline DNA of the CMN syndrome patients to identify the RAS and WNT mutations.</gtr:partnerContribution><gtr:piContribution>My lab developed the mouse model to recapitulate human CMN syndrome and showed that MEK inhibitors suppresses the disease in this mouse.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Constellation Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Investigation of BET and MDM2 inhibitors as a candidate novel combination therapy for Acute Myeloid Leukaemia</gtr:description><gtr:id>5A5A0ADE-7736-4A18-9E55-85B2CEB3EE49</gtr:id><gtr:impact>Application for funding submitted to MRC. Goal is to progress studies to a Phase I clinical trial of the drug combination in AML.</gtr:impact><gtr:partnerContribution>Roche and Constellation provided intellectual advice on use of drugs and free human clinical grade drugs (RG7112 and CPI0610) for use in mouse models. 

Roche also provided 1 year funding for a technician in my lab, Ms. Maria Terradas Terradas</gtr:partnerContribution><gtr:piContribution>My lab performed all the studies in vitro and in mouse models to demonstrate the synergy between MDM2 inhibitors and BET inhibitors against AML.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Structural Genomics Consortium (SGC)</gtr:department><gtr:description>Testing SWI/SNF inhibitors in cancer</gtr:description><gtr:id>93CAFFE7-369F-445B-A2C1-148F7A895416</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:partnerContribution>SGC generated the small molecule inhibitors.</gtr:partnerContribution><gtr:piContribution>We have obtained SWI/SNF inhibitors to test on cancer cell lines. This stems directly from our MRC award, examining the role of SWI/SNF in tumor suppression.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Meeting with BBC producers</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C6ED362F-2134-4600-B00E-BFB93D1EEC66</gtr:id><gtr:impact>Met with BBC producers - Paul Overton and Tas Maqsood -, spoke on phone and exchanged emails re. a BBC show in production on healthy aging, biomarkers to measure healthy aging and interventions to promote healthy aging.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pint of Science talk to public</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2AE55153-EED9-471B-968A-693F2DA77940</gtr:id><gtr:impact>I presented an informal lay talk on cancer and aging - specifically the age dependence of cancer and the importance of diet and exercise to promote healthy aging and suppression of disease such as cancer.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting lay public and donors for Glasgow Wolfson-Wohl Translational Cancer Research Center</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CBA52EA3-49E9-4C8A-B588-AFC6CAE8C781</gtr:id><gtr:impact>About 20 people attended for a short presentation, discussion and bldg tour.

Funds raised and interest generated amongst public.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.gla.ac.uk/about/givingtoglasgow/beatsonpebbleappeal/</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited Speaker at US NIA strategy mtg: Advances in Geroscience: Impact on Healthspan and Chronic Disease</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>412D72B8-A140-4B92-A325-548749FF23A9</gtr:id><gtr:type>Participation in a national consultation</gtr:type><gtr:url>http://chromatin.files.wordpress.com/2008/08/cancer-and-aging.pdf</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>The Structural Genome Consortium (SGC) has developed small molecule inhibtors for SWI/SNF - PFI-3. In line with the goals of the MRC award, we are testing this inhibitor for toxicity towards cancer cell lines with mutations in the SWI/SNF subunit, ARID1a/b.</gtr:description><gtr:id>FAF5AF21-D209-4A32-BAFC-7F3B0A35F912</gtr:id><gtr:impact>Potential to be novel anti-cancer therapeutic targeted to cancers with Arid1/b mutations.</gtr:impact><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PFI-3</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.thesgc.org/scientists/chemical_probes/PFI-3.</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>A shared database of whole genome sequencing data of the epigenome of senescent cells, shared by my lab, Shelley Berger's lab Philadelphia, and made available to other researchers in the field, including John Sedivy, Nicola Neretti and others.</gtr:description><gtr:id>2E2C6CF6-ADE5-4B52-80FF-2DF645EC3B75</gtr:id><gtr:impact>The shared data between labs has been invaluable for hypothesis generation.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Senescence-epigenome</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A mouse model that closely recapitulates genetics and phenotype of human CMN syndrome.</gtr:description><gtr:id>070978EF-E97C-43EA-8B59-EC043AE3DB7C</gtr:id><gtr:impact>We demonstrated the value of MEK inhibitors as a candidate therapy for human CMN syndrome.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mouse model of human CMN syndrome</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/570BA18C-9FB7-4A84-8B4B-0F6BAD733CFD"><gtr:id>570BA18C-9FB7-4A84-8B4B-0F6BAD733CFD</gtr:id><gtr:title>Mitotic Stress Is an Integral Part of the Oncogene-Induced Senescence Program that Promotes Multinucleation and Cell Cycle Arrest.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/31152bac48c9c30ed7c2810018c35491"><gtr:id>31152bac48c9c30ed7c2810018c35491</gtr:id><gtr:otherNames>Dikovskaya D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5049382A-26BC-42C5-9ED5-4E0BA53CAB68"><gtr:id>5049382A-26BC-42C5-9ED5-4E0BA53CAB68</gtr:id><gtr:title>Transcription factor EKLF (KLF1) recruitment of the histone chaperone HIRA is essential for ?-globin gene expression.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4bc05db55e7cae02d0ea5bb1b33bf625"><gtr:id>4bc05db55e7cae02d0ea5bb1b33bf625</gtr:id><gtr:otherNames>Soni S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100054</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>